Date published: 2025-10-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

Zaprinast (M&B 22948) (CAS 37762-06-4)

5.0(2)
Write a reviewAsk a question

See product citations (8)

Alternate Names:
1,4-Dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo(4,5-d)pyrimidin-7-one; 2-(o-Propoxyphenyl)-8-azapurin-6-one
Application:
Zaprinast (M&B 22948) is an inhibitor of cGMP-specific phosphodiesterase
CAS Number:
37762-06-4
Purity:
≥98%
Molecular Weight:
271.27
Molecular Formula:
C13H13N5O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Zaprinast, known as M&B 22948, is utilized in biochemistry and molecular biology research for its properties as a selective inhibitor of the enzyme phosphodiesterase 5 (PDE5). In experimental studies, Zaprinast (M&B 22948) helps elucidate the role of cyclic guanosine monophosphate (cGMP) in cellular signaling by preventing cGMP breakdown. This action provides researchers with the means to dissect the pathways that rely on cGMP as a second messenger, which are important for understanding various biological responses. The compound is also useful in the study of phototransduction in retinal research as it assists in the investigation of the effects of cGMP in visual processes. Moreover, Zaprinast (M&B 22948) is instrumental in research into the intracellular mechanisms that control platelet function.


Zaprinast (M&B 22948) (CAS 37762-06-4) References

  1. Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil.  |  Gibson, A. 2001. Eur J Pharmacol. 411: 1-10. PMID: 11137852
  2. Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons.  |  Nakamizo, T., et al. 2003. J Neurosci Res. 71: 485-95. PMID: 12548704
  3. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.  |  Merkel, LA., et al. 1992. Eur J Pharmacol. 216: 29-35. PMID: 1326438
  4. Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35.  |  Taniguchi, Y., et al. 2006. FEBS Lett. 580: 5003-8. PMID: 16934253
  5. Inhibition of low Km cyclic GMP phosphodiesterases and potentiation of guanylate cyclase activators by cicletanine.  |  Silver, PJ., et al. 1990. J Cardiovasc Pharmacol. 16: 501-5. PMID: 1700224
  6. Inhibition of N-type calcium channels by activation of GPR35, an orphan receptor, heterologously expressed in rat sympathetic neurons.  |  Guo, J., et al. 2008. J Pharmacol Exp Ther. 324: 342-51. PMID: 17940199
  7. Sodium nitroprusside potentiates the depressor response to the phosphodiesterase inhibitor zaprinast in rats.  |  Dundore, RL., et al. 1990. Eur J Pharmacol. 185: 91-7. PMID: 1977600
  8. G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast.  |  Cosi, C., et al. 2011. Neuropharmacology. 60: 1227-31. PMID: 21110987
  9. Zaprinast activates MAPKs, NFκB, and Akt and induces the expressions of inflammatory genes in microglia.  |  Lee, HS., et al. 2012. Int Immunopharmacol. 13: 232-41. PMID: 22561121
  10. GPR35 activation reduces Ca2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapses.  |  Berlinguer-Palmini, R., et al. 2013. PLoS One. 8: e82180. PMID: 24312407
  11. Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina.  |  Martínez-Fernández de la Cámara, C., et al. 2014. J Neuroinflammation. 11: 172. PMID: 25301432
  12. Kynurenic acid and zaprinast induce analgesia by modulating HCN channels through GPR35 activation.  |  Resta, F., et al. 2016. Neuropharmacology. 108: 136-43. PMID: 27131920
  13. Activation of the NO-cGMP signalling pathway depresses hippocampal synaptic transmission through an adenosine receptor-dependent mechanism.  |  Broome, MR., et al. 1994. Neuropharmacology. 33: 1511-3. PMID: 7870292

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Zaprinast (M&B 22948), 25 mg

sc-201206
25 mg
$103.00

Zaprinast (M&B 22948), 100 mg

sc-201206A
100 mg
$245.00